trending Market Intelligence /marketintelligence/en/news-insights/trending/offagx_62brjlazfqqlraq2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

AstraZeneca, Merck & Co.'s Lynparza gets US FDA orphan-drug status

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


AstraZeneca, Merck & Co.'s Lynparza gets US FDA orphan-drug status

AstraZeneca PLC said the U.S. Food and Drug Administration granted orphan-drug status to its drug Lynparza for pancreatic cancer drug.

Cambridge, U.K.-based AstraZeneca is evaluating Lynparza against placebo in a late-stage pancreatic cancer study, called Polo, with results expected in the first half of 2019.

The drug, which AstraZeneca is developing with Merck & Co. Inc., was previously designated an orphan drug for treatment of ovarian cancer, fallopian tube cancer and primary peritoneal cancer.

Lynparza, also known as olaparib, is already approved to treat adults with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who have had their tumor shrink at least 50% through chemotherapy.

The U.S. FDA's orphan-drug program encourages the development of rare disease therapies through incentives, such as market exclusivity and relief from certain regulatory fees.

Pancreatic cancer accounts for about 3% of all cancers in the U.S., with five-year survival rates at 8.5%. AstraZeneca Chief Medical Officer Sean Bohen said pancreatic cancer is an area of significant unmet clinical need.